PROCEPT BioRobotics 2024年第四季度GAAP每股亏损$(0.35),低于预期$(0.33),销售额$68.2M,高于预期$66.78M

财报速递2025-02-26
PROCEPT BioRobotics(纳斯达克股票代码:PRCT)报告第四季度每股亏损$(0.35),低于分析师普遍预期的$(0.33),低于6.06%。这一数据较去年同期每股亏损$(0.54)增长了35.19%。公司报告季度销售额为$68.2百万,高于分析师普遍预期的$66.78百万,上涨了2.13%。这一数据较去年同期的销售额$43.581百万增长了56.49%。

以上内容来自Benzinga Earnings专栏,原文如下:

PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 6.06 percent. This is a 35.19 percent increase over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $68.200 million which beat the analyst consensus estimate of $66.780 million by 2.13 percent. This is a 56.49 percent increase over sales of $43.581 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法